<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>KFF Health News</provider_name><provider_url>https://kffhealthnews.org</provider_url><author_name>brilabuskes</author_name><author_url>https://kffhealthnews.org/news/author/brilabuskes/</author_url><title>First Nonopioid Treatment To Ease Withdrawal Symptoms Approved By FDA - KFF Health News</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="egDn86cx3C"&gt;&lt;a href="https://kffhealthnews.org/morning-breakout/first-nonopioid-treatment-to-ease-withdrawal-symptoms-approved-by-fda/"&gt;First Nonopioid Treatment To Ease Withdrawal Symptoms Approved By FDA&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://kffhealthnews.org/morning-breakout/first-nonopioid-treatment-to-ease-withdrawal-symptoms-approved-by-fda/embed/#?secret=egDn86cx3C" width="600" height="338" title="&#x201C;First Nonopioid Treatment To Ease Withdrawal Symptoms Approved By FDA&#x201D; &#x2014; KFF Health News" data-secret="egDn86cx3C" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>Regulators say that Lucemyra is not an addiction medicine but that it can be part of a longer-term treatment plan. "The physical symptoms of opioid withdrawal can be one of the biggest barriers for patients seeking help and ultimately overcoming addiction," says Dr. Scot Gottlieb, the FDA's commissioner.</description></oembed>
